STOCK TITAN

Pharmaceuticals in the Environment

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Alkermes (ALKS) focuses on environmental responsibility and biodiversity conservation in its operations. The company implements strict protocols to mitigate environmental impacts, partners with experts to understand eco-toxicology, and enhances biodiversity at its facilities. Alkermes aims to become more environmentally sustainable through science- and data-driven strategies.
Positive
  • None.
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / November 29, 2023 / Alkermes

Originally published in Alkermes September 2023 Corporate Responsibility Report

We understand the significant potential impacts that pharmaceuticals can have on the environment. We maintain strict internal protocols to adhere to the parameters of our applicable licenses and permits, mitigate the impacts of our operations on natural resources such as surface water and groundwater, and assist us in effectively controlling our air and wastewater emissions.

As part of our development and manufacturing scale-up of new, proprietary molecules, we have implemented programs to enable us to understand and mitigate associated environmental impacts. For example, we partner with third-party experts to identify practices to assist us in characterizing and understanding appropriate eco-toxicology and safe discharge limits.

We have implemented science- and data-driven environmental risk mitigation strategies and continually evaluate opportunities to improve our emissions control systems in order to better protect the environment and enhance the environmental sustainability of our operations.

Preserving the Biodiversity of our Local Communities

Alkermes is committed to conserving and enhancing biodiversity in the local communities where we operate. We recognize the importance of protecting natural areas and habitats. In this context, we established a biodiversity action plan in 2019, which includes assessment of opportunities to enhance biodiversity at our sites.

At our Wilmington facility, we conducted a full-site survey and developed a plan to convert 12 acres of planted grassland into a pollinator field. Twenty-five unique species of plants were planted to increase site biodiversity, which are expected to become full grown by 2026. A maintenance plan was also established to drive plant and insect diversity.

At our Athlone facility, employees have undertaken various actions to preserve and promote local plant and animal life around our site. In 2022, we completed planting of a "pollinator garden" to support local plant and animal populations.

Read more

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com.

Contact Info:
Spokesperson: Alkermes
Website: https://www.3blmedia.com/profiles/alkermes
Email: info@3blmedia.com

SOURCE: Alkermes



View source version on accesswire.com:
https://www.accesswire.com/811418/pharmaceuticals-in-the-environment

Alkermes maintains strict internal protocols to mitigate the impacts of its operations on natural resources and control air and wastewater emissions. The company also implements science- and data-driven environmental risk mitigation strategies.

Alkermes is committed to conserving and enhancing biodiversity in the local communities where it operates. The company has established a biodiversity action plan and implemented initiatives such as converting planted grassland into a pollinator field and planting a 'pollinator garden' to support local plant and animal populations.

The ticker symbol for Alkermes is ALKS.

You can find Alkermes' Corporate Responsibility Report on their website at https://www.3blmedia.com/profiles/alkermes.

You can reach Alkermes via email at info@3blmedia.com.
Alkermes Inc. plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

4.15B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 4

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.